Focus: Mendaera is a medical robotics company specializing in percutaneous guidance systems for neurology and related procedural interventions. The company operates as a pre-revenue biotech focused on device-based solutions for minimally invasive access.
Profile data last refreshed 1h ago · AI intelligence enriched 3w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Mendaera is a high-risk, early-stage medical robotics play suitable for career-builders seeking deep technical involvement in device innovation, but unsuitable for those prioritizing financial stability or near-term product launches.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Mendaera
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Mendaera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
A needle-guidance robot brings Butterfly’s first partner technology to market. - Stock Titan
A needle-guidance robot brings Butterfly’s first partner technology to market. Stock Titan
New Peer-Reviewed Study Shows 98% Technical Success for Mendaera's Focalist™ System Across Urology, Anesthesiology, and Nephrology - PR Newswire
New Peer-Reviewed Study Shows 98% Technical Success for Mendaera's Focalist™ System Across Urology, Anesthesiology, and Nephrology PR Newswire
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles